NHS ‘nowhere near ready’ to deliver new Alzheimer’s drug, doctors say

Patients unlikely to receive lecanemab before 2026 and health service does not yet have necessary infrastructure

A reorganisation of NHS dementia care is needed to ensure UK patients can receive a groundbreaking drug that slows the progression of Alzheimer’s disease, doctors say.

Detailed results from a clinical trial of lecanemab have confirmed that the drug reduces cognitive decline in patients with early-stage Alzheimer’s, in a hard-won breakthrough hailed as a historic moment for the field.

The drug, created by Biogen in the US and Eisai in Japan, is the first to demonstrate that it can change the trajectory of the disease. While the benefit is modest – the drug slowed cognitive decline by 27% over 18 months – doctors believe it has the potential to give patients months more independent living.

The US Food and Drug Administration is expected to approve lecanemab in January, paving the way for US hospitals to start prescribing the drug next year. But the NHS faces an enormous challenge in preparing for the introduction of the drug, doctors say, with patients unlikely to receive it before 2026.

Writing in the Guardian, Jonathan Schott, a professor of neurology at UCL’s Queen Square Institute of Neurology and the chief medical officer at Alzheimer’s Research UK, says the NHS is “nowhere near ready” to deliver lecanemab.

“While some specialist centres have the capabilities required, the wider NHS simply does not have the infrastructure and staff to diagnose potentially eligible patients, nor to deliver the drug, which is given by infusion every two weeks, nor to perform and read multiple MRI safety scans,” he writes.

Other senior doctors share the view. “We are not prepared,” said Dr Liz Coulthard, an assistant professor in dementia neurology at the University of Bristol. “We need a massive change in workforce service delivery.”

Lecanemab is an antibody therapy that targets clumps of protein called beta-amyloid, which build up in patients’ brains. Scientists still debate amyloid’s role in Alzheimer’s, but clearing it from the brain may prevent other pathological processes from taking hold, such as the formation of protein tangles inside brain cells.

Patients who are diagnosed early with mild cognitive impairment due to Alzheimer’s typically have about six years of independent living before they need support at home. If the benefits of lecanemab are sustained over six years, a patient might have 19 more months of independent living, Coulthard said.

“The problem is, we don’t see patients at the mild cognitive impairment stage,” she said. “We don’t have the services. In Bristol, which is not atypical, there is no clinical pathway for mild cognitive impairment. If you get diagnosed with it, you are discharged, and there is hardly ever any follow-up.”

Part of the problem is that most dementia patients in the UK are cared for in memory clinics run by psychiatric or gerontology services, which do not have routine access to Alzheimer’s tests. While blood tests for Alzheimer’s are on the horizon, the disease is currently confirmed by lumbar puncture, which looks for amyloid in spinal fluid, or positron emission tomography (PET) scan, which detects the protein in the brain. Alzheimer’s Research UK estimates that only 2% of patients eligible for lecanemab would have access to the drug under existing testing.

“We’ll need to have new services, either within psychiatry, perhaps referring to neurology for lumbar puncture or scans, or within neurology that can deliver the large numbers of new diagnostic tests that we’ll need to do,” Coulthard said.

Nearly 1 million people in the UK live with dementia, the leading cause of death in the country. Two-thirds of cases are due to Alzheimer’s. The condition causes the relentless destruction of neurons in the brain, driving memory loss, problems with decision-making, and ultimately difficulties with eating, speaking and movement.

Lecanemab would have to be approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute of Health and Care Excellence (Nice) before it could be given by the NHS. MHRA approval could come as early as 2024, with the Nice review taking another year.

“Even if those things were to happen overnight, we would just not be able to deliver this, because of the scale of what is needed,” said Masud Husain, a professor of neurology and cognitive neuroscience at the University of Oxford.

Besides swift and accurate diagnoses to identify those likely to benefit, hospitals would need specialist staff and equipment to provide regular drug infusions and MRI scans to check for side-effects, which include brain swelling. One hope is that the drug can be used in bursts, with patients taking it until their amyloid levels fall, then being monitored to watch for it rising back up.

Prof Paul Matthews, the head of the UK Dementia Research Institute at Imperial College London, said he did not expect the UK to be a “rapid adopter” of lecanemab. This would give time for health officials to assess how effective the drug was in real-world settings and prepare the NHS to deliver it.

Dr Richard Oakley, of the Alzheimer’s Society, said: “We’re on the cusp of exciting new treatments for Alzheimer’s disease, but we need to improve dementia diagnosis in the UK to ensure the right people are getting these drugs when they are most effective. This will involve better access to PET scanners and tests to make sure everyone gets a quick, accurate diagnosis.

“We estimate that at least 106,000 people could benefit from lecanemab if and when it becomes available in the UK. But currently one in six people wait over a year to see a specialist after GP referral, and one in 10 wait over six months for a brain scan.”

Contributor

Ian Sample Science editor

The GuardianTramp

Related Content

Article image
Dismay as Alzheimer's drug fails in clinical trials
Final-stage results dash hopes that solanezumab, an injectable antibody, would provide treatment breakthrough

Hannah Devlin Science correspondent

23, Nov, 2016 @2:48 PM

Article image
Success of experimental Alzheimer’s drug hailed as ‘historic moment’
Study shows cognition in early-stage patients on lecanemab declines by 27% less than those on placebo

Hannah Devlin Science correspondent

28, Sep, 2022 @1:05 PM

Article image
Appeal court ruling gives hope to NHS Alzheimer's patients denied drugs

Court finds government watchdog unfair in refusing to give anti-dementia medicines

James Meikle

02, May, 2008 @7:28 AM

Article image
Dementia and Alzheimer’s main cause of death for women, says Public Health England
Female life expectancy is now 83 years but many women will spend a quarter of their lives in ill-health, finds report

Sarah Boseley Health editor

13, Jul, 2017 @6:12 PM

Article image
Drug slows cognitive decline in Alzheimer’s patients, study reveals
Antibody therapy lecanemab removes clumps of protein called beta amyloid that builds up in brain

Ian Sample Science editor

30, Nov, 2022 @12:50 AM

Article image
NHS postcode lottery survey reveals wide UK disparities
NHS Atlas of Variation, a government analysis of regional treatment, shows huge inequalities in quality, quantity and costs

Randeep Ramesh, social affairs editor

09, Dec, 2011 @5:22 PM

Article image
Living near heavy traffic increases risk of dementia, say scientists
Study tracking 6.6 million people estimates one in 10 cases of Alzheimer’s among those living by busy roads could be linked to air and noise pollution

Hannah Devlin Science correspondent

05, Jan, 2017 @7:25 AM

Article image
Strobe lighting provides a flicker of hope in the fight against Alzheimer’s
Exposure to flashing lights stimulates brain’s immune cells to clean up toxic proteins causing the disease, study finds

Hannah Devlin Science correspondent

07, Dec, 2016 @6:00 PM

Article image
Drug companies accused of spending millions on conference trips for doctors

Sponsorship is a massive marketing exercise dressed up as medical education, say critics

Sarah Boseley and Rob Evans

22, Aug, 2008 @11:01 PM

Article image
Drug maker 'will make $21bn from treating cystic fibrosis'
Vertex is accused of raking in vast profits while making Orkambi unaffordable to NHS

Sarah Boseley Health editor

12, Aug, 2019 @5:00 AM